Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RCEL vs ECOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RCEL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

RCEL Overall Winner 6-Pillar Tally: RCEL 3 – 2 ECOR (1 Tie) Matrix Metrics: RCEL 7 – 3 ECOR

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RCEL carries a Unified Composite Score of 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin), whereas ECOR carries 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin).

  • Technical & Structure Timing Caution: RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RCEL vs ECOR
RCEL NASDAQ Head-to-Head Winner
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.62
-2.31% 1D
Market Cap $506.7M
TTM Revenue $85M
Forward P/E 10.3x
Beta / 30D Vol 1.54β · 65% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 32.0 Fund 44.0 Flow 69.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (21.1% over 20 days), RSI 52
RSI-14: 51.5 · SMA20: $16.14 · SMA50: $13.96
ECOR NASDAQ
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
-8.87% 1D
Market Cap $44.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.55β · 155% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 30.0 Fund 60.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.1%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.77 · SMA50: $8.56

6-Pillar Scorecard Institutional Category Breakdown (RCEL 3 – 2 ECOR)

Columns: Metric · RCEL · ECOR
1. Valuation Multiples RCEL
Forward P/E 10.3x N/M
Trailing P/E 10.3x N/M
PEG Ratio N/M N/M
EV / Revenue 6.4x 1.3x
2. Growth & Scale RCEL
Revenue Growth (YoY) +53.1% +11.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $85M $38M
Market Cap $506.7M $44.7M
3. Profitability & Quality ECOR
Gross Margin 82.4% 87.7%
Operating Margin -33.9% -33.1%
Net Profit Margin -42.6% -33.5%
Return on Equity (ROE) -1746.3% -478.7%
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$20M -$6.9M
Cash Flow Margin -23.6% -18.1%
Net Cash / Leverage $37M Net Debt $4.6M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCEL
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 84.7% (6th %ile) N/A (N/A)
Put/Call OI Skew 0.18x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RCEL (7) vs ECOR (3)
Institutional Metric RCEL ECOR Criterion Row Edge
Market Capitalization
Scale
$506.7M $44.7M Larger Scale RCEL
Trailing P/E Ratio
Valuation
10.3x N/M Lower Multiple RCEL
Forward P/E Ratio
Valuation
10.3x N/M Lower Multiple RCEL
Revenue Growth (YoY)
Growth
+53.1% +11.5% Higher Growth RCEL
Operating Margin (TTM)
Profitability
-33.9% -33.1% Higher Margin ECOR
Net Profit Margin
Profitability
-42.6% -33.5% Higher Margin ECOR
Return on Equity (ROE)
Capital Efficiency
-1746.3% -478.7% Higher ROE ECOR
52-Week Range Position
Momentum
82% ($3–$18) 6% ($4–$13) Stronger Trend RCEL
Beta / 30D Volatility
Risk Regime
1.54β · 65% Vol 1.55β · 155% Vol Lower Realized Risk RCEL
Unified Institutional Score
Composite Signal
45.6 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite RCEL
Trailing 12M Revenue (USD)
Operating Scale
$85M $38M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
82.4% 87.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.4x EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$20M ($37M Net Debt) -$6.9M ($4.6M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RCEL +41.65 pp
RCEL: +1.3% · ECOR: -40.35%
3M Horizon RCEL +111.82 pp
RCEL: +57.62% · ECOR: -54.2%
6M Horizon RCEL +274.78 pp
RCEL: +241.05% · ECOR: -33.73%
1Y Horizon RCEL +304.87 pp
RCEL: +295.44% · ECOR: -9.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RCEL Revenue ECOR Revenue RCEL Op. Margin ECOR Op. Margin Margin Leader
FY2018 $0M $0M -1489.9% -5494.1% RCEL
FY2019 $10M $0M -466.4% -1928.2% RCEL
FY2020 $10M $0M -299.2% -707.9% RCEL
FY2021 $30M $10M -90.8% -367.7% RCEL
FY2022 $30M $10M -79.9% -266.2% RCEL
FY2023 $50M $20M -85.1% -120.2% RCEL
FY2024 $60M $30M -88.1% -48.3% ECOR
FY2025 $70M $30M -59.4% -41.1% ECOR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RCEL CONSOLIDATION
17d in phase · OBV NEUTRAL
Current IV 84.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RCEL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $506.7M market capitalization and -33.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $44.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RCEL vs ECOR Key Questions & Quantitative Answers

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RCEL carries a Unified Composite Score of 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin), whereas ECOR carries 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin). Technical & Structure Timing Caution: RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RCEL leads the Growth & Scale pillar: RCEL posts +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin), compared with ECOR at +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RCEL cumulative revenue shifted +600.0% while ECOR shifted +200.0%. In operating R&D and SG&A reinvestment, RCEL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ECOR.

RCEL screens cheaper on headline valuation multiples. RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin), whereas ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-18.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RCEL (-1746.3% ROE) versus ECOR (-478.7% ROE) capital efficiency.

In options market volatility and institutional positioning, RCEL carries 84.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.54β · 65% Vol realized risk). By comparison, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 155% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.